Le Lézard
Classified in: Health
Subject: LAW

PharmacyChecker Statement on Federal Court's Denial of LegitScript's Motion to Block Antitrust Lawsuit


WHITE PLAINS, N.Y., Jan. 8, 2024 /PRNewswire/ -- In response to U.S. District Judge Michael H. Simon's January 3, 2023, ruling to deny a motion by LegitScript, LLC for summary judgment and to stay discovery in an antitrust lawsuit filed against it by PharmacyChecker.com, LLC, PharmacyChecker's management released the following statement:

We are gratified that the court has rejected LegitScript's attempts to immunize itself against this antitrust action, in which PharmacyChecker alleges an unlawful conspiracy by LegitScript and other defendants to suppress information that PharmacyChecker provides to help patients identify online pharmacies that sell genuine, safe, and affordable prescription medication, including through personal importation.

We look forward to continuing our fight for competition and transparency in prescription drug pricing, unhindered by defense attempts to distract from the illegal conduct of LegitScript and its co-conspirators that this lawsuit alleges and seeks to address.

In his ruling, Judge Simon wrote, "Based on the facts and law presented by the parties, the Court concludes that PharmacyChecker's business is legal. LegitScript has identified no federal or state law that PharmacyChecker has violated. Nor has LegitScript pointed to any instance of a federal or state law enforcement agency prosecuting or even threatening to prosecute PharmacyChecker, or any instance of a federal or state regulatory body taking or even threatening to take any action against PharmacyChecker (e.g., by issuing a cease-and-desist order). Nor, for that matter, has LegitScript shown that visitors to PharmacyChecker's website?including those visitors who click on links to non-U.S. pharmacies?engage in illegal activity simply by using PharmacyChecker's website."

Judge Simon pointed out that "It would contravene Supreme Court and Ninth Circuit precedent for this court to fashion a new rule that deprives a plaintiff of an antitrust cause of action and immunize an antitrust defendant when the plaintiff's business is entirely legal."

Justice has prevailed. Judge Simon has deemed PharmacyChecker's work to help patients find affordable medication legal, and its case against LegitScript moves forward.

With the Oregon court agreeing with PharmacyChecker's positions on key issues of fact and law, PharmacyChecker plans to appeal a New York district court's April 2023 partial opinion which stalled the case there against alleged co-conspirators the Alliance for Safe Online Pharmacies, Center for Safe Internet Pharmacies, National Association of Boards of Pharmacy, and Partnership for Safe Medicines. 

ABOUT PHARMACYCHECKER.COM

Launched in 2003 by Tod Cooperman, M.D. and Gabriel Levitt, PharmacyChecker.com helps people find the lowest prices on prescription medication among licensed pharmacies located across the globe. It is the only independent company that verifies and monitors the credentials of international online pharmacies and compares the prices of the prescription drugs available from these licensed pharmacies. PharmacyChecker fills a critical need for patients worldwide to find affordable and accessible prescription medications.

SOURCE PharmacyChecker.com


These press releases may also interest you

at 21:07
Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010...

at 20:51
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...

at 20:30
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...

at 20:05
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...



News published on and distributed by: